Mechanisms of human immune modulation by oral N-acetylglucosamine

口服N-乙酰氨基葡萄糖调节人体免疫的机制

基本信息

  • 批准号:
    9272357
  • 负责人:
  • 金额:
    $ 40.87万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-06-01 至 2019-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Our published data in mice has revealed that the simple sugar and dietary supplement N- acetylglucosamine (GlcNAc) inhibits T cell function and autoimmunity by enhancing N-glycosylation in T cells. Virtually all cell surface and secreted proteins in metazoans are modified by the addition of complex carbohydrates in the ER/Golgi secretory pathway, imparting substantial molecular information not encoded by the genome. We find that genetic, metabolic and environmental regulation of Golgi N-glycosylation controls macromolecular complexes on the cell surface to influence cell growth, differentiation and disease states. The branching and number of N-glycans per protein molecule cooperate to regulate binding to galectins, forming a galectin-glycoprotein lattice that controls the distributin, clustering and endocytosis of surface glycoproteins in a predictable manner. N-glyan branching deficiency induces T cell hyper-activity and spontaneous autoimmune disease in mice by enhancing T cell receptor clustering/signaling, reducing surface retention of the growth inhibitors CTLA-4 and TGF-ßRI/II and promoting differentiation into pro-inflammatory TH1/TH17 cells. In humans, multiple genetic and environmental risk factors for Multiple Sclerosis (MS) converge to dysregulate N- glycosylation and CTLA-4 surface retention. These include genetic variants in interleukin-7 receptor-α, interleukin-2 receptor-α, MGAT1, MGAT5 and CTLA-4 as well as Vitamin D3 and metabolic production of UDP-GlcNAc, the substrate for MGAT1 and MGAT5. Rescuing N-glycan branching deficiency in T cells in vitro and in vivo by metabolically increasing UDP-GlcNAc with the dietary supplement N-acetylglucosamine (GlcNAc), suppresses T cell growth, enhances CTLA-4 and TGF-ßRI/II surface expression, blocks TH1/TH17 differentiation, inhibits MS and autoimmune diabetes models and rescues N-glycan branching deficiency induced by MS genetic risk factors. Therapeutic supplementation to N-glycan biosynthesis with GlcNAc may provide a personalized medicine approach to suppress an underlying molecular defect promoting human autoimmunity. Here we propose to examine whether oral GlcNAc in humans enhances N-glycan branching to suppress T cell function and induce immune deviation, focusing on individuals with genetic polymorphisms that promote MS and down-regulate N-glycan branching in T cells. Specific Aim 1 examines whether in vitro GlcNAc regulates hypomorphic N-glycan branching in male vs female human T cells to suppress pro- autoimmune TH1/TH17 cells while enhancing anti-autoimmune T regulatory cells. Specific Aim 2 examines whether oral GlcNAc enhances N-glycan branching to suppress pro-autoimmune TH1/TH17 responses while enhancing anti-autoimmune T regulatory cells in MS patients with genetic defects in N-glycosylation.
描述(申请人提供):我们在小鼠身上发表的数据显示,单糖和膳食补充剂N-乙酰氨基葡萄糖(GlcNAc)通过增强T细胞中的N-糖基化来抑制T细胞功能和自身免疫。事实上,后生动物的所有细胞表面和分泌的蛋白质都是通过在内质网/高尔基体分泌途径中添加复杂的碳水化合物来修饰的,提供了大量不被基因组编码的分子信息。我们发现高尔基体N-糖基化的遗传、代谢和环境调节控制着细胞表面的大分子复合体,从而影响细胞的生长、分化和疾病状态。每个蛋白质分子的支链和N-糖链的数量共同调节与Galectins的结合,形成Galectin-糖蛋白晶格,以可预测的方式控制表面糖蛋白的分布、聚集和内吞。N-葡聚糖分支缺陷通过增强T细胞受体聚集/信号传递,减少生长抑制物的表面滞留,诱导小鼠T细胞高活性和自发性自身免疫性疾病 CTLA-4和转化生长因子-B受体RI/II,并促进分化为促炎的TH1/TH17细胞。在人类中,多发性硬化症(MS)的多种遗传和环境危险因素汇聚在一起,导致N-糖基化和CTLA-4表面滞留的失调。包括白介素7受体α、白介素2受体α、MGAT1、MGAT5和CTLA-4的遗传变异,以及维生素D3和代谢产物UDP-GlcNAc,MGAT1和MGAT5的底物。通过补充N-乙酰氨基葡萄糖(GlcNAc)通过代谢增加UDP-GlcNAc来挽救体外和体内T细胞的N-糖链分支缺陷,抑制T细胞的生长,增强CTLA-4和转化生长因子-βRI/II的表面表达,阻断TH1/TH17的分化,抑制MS和自身免疫性糖尿病模型,并挽救由MS遗传危险因素引起的N-糖链分支缺陷。使用GlcNAc对N-糖链生物合成进行治疗性补充,可能会提供一种个性化的药物途径,以抑制促进人类自身免疫的潜在分子缺陷。在这里,我们建议研究人类口服GlcNAc是否增强N-糖链分支以抑制T细胞功能和诱导免疫偏离,重点关注具有促进多发性硬化和下调T细胞N-糖链分支的遗传多态的个体。特异性目的1研究GlcNAc是否在体外调节男性和女性人类T细胞中N-糖链的低形态分支,以抑制前自身免疫的TH1/TH17细胞,同时增强抗自身免疫的T调节细胞。特定目的2检查口服GlcNAc是否增强N-糖链分支以抑制前自身免疫TH1/TH17反应,同时增强N-糖基化遗传缺陷的MS患者的抗自身免疫T调节细胞。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

MICHAEL DEMETRIOU其他文献

MICHAEL DEMETRIOU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('MICHAEL DEMETRIOU', 18)}}的其他基金

Extended half-life GlyTR1 combined with checkpoint blockade for Cancer Immunotherapy
延长半衰期的 GlyTR1 与检查点阻断相结合用于癌症免疫治疗
  • 批准号:
    10766646
  • 财政年份:
    2023
  • 资助金额:
    $ 40.87万
  • 项目类别:
Cancer Immunotherapy Targeting Tn Antigen
针对 Tn 抗原的癌症免疫疗法
  • 批准号:
    10326021
  • 财政年份:
    2021
  • 资助金额:
    $ 40.87万
  • 项目类别:
Regulation of B cell function in demyelinating disease by N-glycan branching
N-聚糖分支调节脱髓鞘疾病中的 B 细胞功能
  • 批准号:
    10311524
  • 财政年份:
    2019
  • 资助金额:
    $ 40.87万
  • 项目类别:
Regulation of B cell function in demyelinating disease by N-glycan branching
N-聚糖分支调节脱髓鞘疾病中的 B 细胞功能
  • 批准号:
    10535482
  • 财政年份:
    2019
  • 资助金额:
    $ 40.87万
  • 项目类别:
N-glycosylation and Immunotherapy for cancer
N-糖基化和癌症免疫治疗
  • 批准号:
    10465041
  • 财政年份:
    2018
  • 资助金额:
    $ 40.87万
  • 项目类别:
N-glycosylation and Immunotherapy for cancer
N-糖基化和癌症免疫治疗
  • 批准号:
    10229448
  • 财政年份:
    2018
  • 资助金额:
    $ 40.87万
  • 项目类别:
O-Glycan-dependent Immunotherapy for Cancer
O-聚糖依赖性癌症免疫疗法
  • 批准号:
    9988594
  • 财政年份:
    2018
  • 资助金额:
    $ 40.87万
  • 项目类别:
N-glycosylation and Immunotherapy for cancer
N-糖基化和癌症免疫治疗
  • 批准号:
    9789858
  • 财政年份:
    2018
  • 资助金额:
    $ 40.87万
  • 项目类别:
N-glycosylation and Immunotherapy for cancer
N-糖基化和癌症免疫治疗
  • 批准号:
    10005189
  • 财政年份:
    2018
  • 资助金额:
    $ 40.87万
  • 项目类别:
Mechanisms of human immune modulation by oral N-acetylglucosamine
口服N-乙酰氨基葡萄糖调节人体免疫的机制
  • 批准号:
    8851521
  • 财政年份:
    2014
  • 资助金额:
    $ 40.87万
  • 项目类别:

相似海外基金

The earliest exploration of land by animals: from trace fossils to numerical analyses
动物对陆地的最早探索:从痕迹化石到数值分析
  • 批准号:
    EP/Z000920/1
  • 财政年份:
    2025
  • 资助金额:
    $ 40.87万
  • 项目类别:
    Fellowship
Animals and geopolitics in South Asian borderlands
南亚边境地区的动物和地缘政治
  • 批准号:
    FT230100276
  • 财政年份:
    2024
  • 资助金额:
    $ 40.87万
  • 项目类别:
    ARC Future Fellowships
The function of the RNA methylome in animals
RNA甲基化组在动物中的功能
  • 批准号:
    MR/X024261/1
  • 财政年份:
    2024
  • 资助金额:
    $ 40.87万
  • 项目类别:
    Fellowship
Ecological and phylogenomic insights into infectious diseases in animals
对动物传染病的生态学和系统发育学见解
  • 批准号:
    DE240100388
  • 财政年份:
    2024
  • 资助金额:
    $ 40.87万
  • 项目类别:
    Discovery Early Career Researcher Award
Zootropolis: Multi-species archaeological, ecological and historical approaches to animals in Medieval urban Scotland
Zootropolis:苏格兰中世纪城市动物的多物种考古、生态和历史方法
  • 批准号:
    2889694
  • 财政年份:
    2023
  • 资助金额:
    $ 40.87万
  • 项目类别:
    Studentship
Using novel modelling approaches to investigate the evolution of symmetry in early animals.
使用新颖的建模方法来研究早期动物的对称性进化。
  • 批准号:
    2842926
  • 财政年份:
    2023
  • 资助金额:
    $ 40.87万
  • 项目类别:
    Studentship
Study of human late fetal lung tissue and 3D in vitro organoids to replace and reduce animals in lung developmental research
研究人类晚期胎儿肺组织和 3D 体外类器官在肺发育研究中替代和减少动物
  • 批准号:
    NC/X001644/1
  • 财政年份:
    2023
  • 资助金额:
    $ 40.87万
  • 项目类别:
    Training Grant
RUI: Unilateral Lasing in Underwater Animals
RUI:水下动物的单侧激光攻击
  • 批准号:
    2337595
  • 财政年份:
    2023
  • 资助金额:
    $ 40.87万
  • 项目类别:
    Continuing Grant
RUI:OSIB:The effects of high disease risk on uninfected animals
RUI:OSIB:高疾病风险对未感染动物的影响
  • 批准号:
    2232190
  • 财政年份:
    2023
  • 资助金额:
    $ 40.87万
  • 项目类别:
    Continuing Grant
A method for identifying taxonomy of plants and animals in metagenomic samples
一种识别宏基因组样本中植物和动物分类的方法
  • 批准号:
    23K17514
  • 财政年份:
    2023
  • 资助金额:
    $ 40.87万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了